Education
About Us
Working with TipRanks
Follow Us
Y-Mabs Therapeutics (YMAB)
NASDAQ:YMAB
RESEARCH TOOLSreports
YMAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.28 - $19.12
Previous CloseN/A
Volume43.26K
Average Volume (3M)492.45K
Market Cap
$249.03M
Enterprise Value$519.80M
Total Cash (Recent Filing)$78.64M
Total Debt (Recent Filing)$1.42M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Mar 04, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding44,789,078
10 Day Avg. Volume435,199
30 Day Avg. Volume492,448
Standard Deviation0.24
R-Squared0.02
Alpha-0.00486
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.95
Price to Cash Flow (P/CF)-5.80
P/FCF Ratio0.00
Enterprise Value/Market Cap2.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.08
Enterprise Value/Ebitda-18.65
Forecast
1Y Price Target
$19.43Price Target Upside249.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
---
Y-Mabs Therapeutics News
PremiumCompany Announcements
Y-mAbs Therapeutics Updates on Business and Clinical Trials
PremiumCompany Announcements
Y-mAbs Therapeutics Announces Strategic Business Realignment
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsYMAB is enrolling participants in its Phase I trial of CD38-SADA PRIT with Lu-177-DOTA for the treatment of relapsed or refractory Non-Hodgkin Lymphoma.
Strategic GrowthY-mAbs optimizes its corporate structure by establishing two business units to accelerate clinical development and optimize the commercial potential of DANYELZA.
Bears Say
Financial Performance2Q24 DANYELZA (naxitamab) revenue of $22.8M came in slightly below our estimate of $24.4M and consensus of $23M.
---
Ownership Overview
23.86% Insiders
7.72% Mutual Funds
<0.01% Other Institutional Investors
57.60% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
YMAB FAQ
What was Y-Mabs Therapeutics’s price range in the past 12 months?
Y-Mabs Therapeutics lowest stock price was $5.28 and its highest was $19.12 in the past 12 months.
What is Y-Mabs Therapeutics’s market cap?
Y-Mabs Therapeutics’s market cap is $249.03M.
When is Y-Mabs Therapeutics’s upcoming earnings report date?
Y-Mabs Therapeutics’s upcoming earnings report date is Mar 04, 2025 which is tomorrow.
How were Y-Mabs Therapeutics’s earnings last quarter?
Y-Mabs Therapeutics released its earnings results on Nov 08, 2024. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.158 by -$0.002.
Is Y-Mabs Therapeutics overvalued?
According to Wall Street analysts Y-Mabs Therapeutics’s price is currently Undervalued.
Does Y-Mabs Therapeutics pay dividends?
Y-Mabs Therapeutics does not currently pay dividends.
What is Y-Mabs Therapeutics’s EPS estimate?
Y-Mabs Therapeutics’s EPS estimate is -0.11.
How many shares outstanding does Y-Mabs Therapeutics have?
Y-Mabs Therapeutics has 44,789,078 shares outstanding.
What happened to Y-Mabs Therapeutics’s price movement after its last earnings report?
Y-Mabs Therapeutics reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.158. Following the earnings report the stock price went down -0.45%.
Which hedge fund is a major shareholder of Y-Mabs Therapeutics?
Currently, no hedge funds are holding shares in YMAB
---
Y-Mabs Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.43 (249.46% Upside)
$19.43 (249.46% Upside)
Blogger Sentiment
Bearish
YMAB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 17.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 6.8%
Last 30 Days ▼ 6.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.95%
12-Months-Change
Fundamentals
Return on Equity
-24.78%
Trailing 12-Months
Asset Growth
-6.18%
Trailing 12-Months
Company Description
Y-Mabs Therapeutics
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company's services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
---
YMAB Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
While Y-mAbs demonstrated strategic growth through partnerships and clinical advancements, the company faced revenue declines and increased operating expenses. Despite progress in physician adoption and ex-U.S. market expansion, challenges in the U.S. market and overall financial performance were notable.Read More>---
YMAB Stock 12 Month Forecast
Average Price Target
$19.43
▲(249.46% Upside)
Technical Analysis
Best Analysts Covering YMAB
1 Year
1 Year Success Rate
8/12 ratings generated profit
1 Year Average Return
+57.97%
reiterated a buy rating 10 months ago
Copying William Maughan's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +57.97% per trade.
---